DOI: http://dx.doi.org/10.18203/2349-3933.ijam20190085

Prospective and retrospective study of weekly intermittent hormone (estrogen and progesterone) replacement therapy in hysterectomised women

Dharmendra Jhavar, Nikhil Jalori, Hemlata Jharbade, Archana Verma

Abstract


Background: Estrogen therapy in younger postmenopausal women is associated with a decisive reduction in morbidity and mortality, but estrogen use in this population is low because of risk of side effects. Weekly intermittent therapy is a more patient friendly approach with reduced pill burden increasing compliance and adherence as well as reducing side effects. Therefore, authors wanted to study the effect of weekly intermittent fixed dose estrogen and progesterone (ultra-low dose) supplements in hysterectomised surgically menopaused women.

Methods: The present study was prospective and retrospective study. For retrospective study authors records of 100 hysterectomised women up to 45years of age with severe post-menopausal symptoms treated in authors Medicine Department of Hospital with once weekly MALA-D tablets were studied. For prospective study, all consecutive hysterectomised patients with severe post-menopausal symptoms attending medicine OPD were given once weekly MALA-D which contains ethinylestradiol 0.03mg and levonorgestrel 0.15mg tablets and followed up monthly with outcomes measured by Modified Kuppermann Index, visual analogue scale, and women’s health questionnaires.

Results: Present retrospective study showed moderate degree of postmenopausal symptoms as indicated by Modified Kuppermann index of 19.57. Prospective study showed significant improvement in postmenopausal symptoms with weekly intermittent hormone replacement therapy as indicated by outcomes measured by Modified Kupperman index and Visual analogue scale. Women’s health questionnaire also showed statistically significant improvement in 6 out of 8 dimensions.

Conclusions: Authors concluded that weekly estrogen progesterone hormone replacement therapy with mala-D tablet (ultra-low dose therapy) was 100% effective in relieving vasomotor symptoms and it is very effective in improving psychosomatic symptoms, urinary symptoms and quality of life with no obvious side effects and greater adherence.


Keywords


HRT, Post menopausal symptoms, Vasomotor symptoms

Full Text:

PDF

References


Archer DF. Premature menopause increases cardiovascular risk. Climacteric. 2009 Jan 1;12(sup1):26-31.

Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis (MESA). Menopause (New York, NY). 2012 Oct;19(10):1081-7.

Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause. 2007 May 1;14(3):567-71.

Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010 Feb 1;65(2):161-6.

Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol. 1998 May 31;8(4):229-35.

Nelson HD. Menopause. Lancet. 2008;371(9614):760-7.

Hoffman, Schorge, Schaffer, Halvorson, Bradshaw, Cunningham: Reproductive endocrinology, Infertility and menopause: Menopausal transition: William’S Textbook of Gynecology: 2nd edition: China: McGraw-Hill;6:562

Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral Contraception. 2013 Jun;87(6):706-27.

Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug 1;8(sup1):3-63.

Skouby SO, Al-Azzawi F, Barlow D, Ertüngealp JC, Gompel A, Graziottin A, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri-and postmenopausal hormone replacement therapy. Maturitas. 2005 May 16;51(1):8-14.

Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metabolism. 2010 Jul 1;95(7_supplement_1):s1-66.

Gurney EP, Nachtigall MJ, Nachtigall LE, Naftolin F. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. J Steroid Biochem Molecular Biol. 2014 Jul 1;142:4-11.

Bassuk SS, Manson JE. Menopausal hormone therapy and cardiovascular disease risk: utility of biomarkers and clinical factors for risk stratification. Clin Chem. 2014 Jan 1;60(1):68-77.

JoAnn E. Manson, Shari S. Bassuk. Menopause and Postmenopausal Hormone Therapy: Harrison’s Principles of Internal Medicine, 19th ed:1; 2384.

Kupperman HS, Wetchler BB, Blatt MH. Contemporary therapy of the menopausal syndrome. J Am Med Assoc. 1959 Nov 21;171(12):1627-37.

Mottola CA. Measurement strategies: the visual analogue scale. Decubitus. 1993 Sep;6(5):56-8.

De Boer AG, van Lanschot JJ, Stalmeier PF, van Sandick JW, Hulscher JB, de Haes JC, et al. Is a single-item visual analogue scale as valid, reliable, and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13:311-20.

Hunter M. The Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychol Health. 1992 Oct 1;7(1):45-54.

Girod I, Abetz L, de la Loge C. Women's Health Questionnaire - User Manual. MAPI Research Institute. 2004:3-56.

Sarrel PM1, Njike VY. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013 Sep;103(9):1583-8.

Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric. 2000 Jan 1;3(3):176-82.

Speroff L, Symons J, Kempfert N, Rowan J, FEMHRT study investigators. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt®) on the frequency and intensity of vasomotor symptoms. Menopause. 2000 Nov 1;7(6):383-90.

Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001 Jun 1;75(6):1065-79.

Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996 Oct 12;348(9033):981-3.

Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000 Dec 19;133(12):933-41.